StartUps and SMEs

The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.

EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.

Interviews during the J.P. Morgan Healthcare Conference and commentary at the Biotech Showcase foresaw a strong 2026 almost across the board for drug developers seeking funding.

From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.

EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.

Gero AI has secured major pharma partnerships in aging space despite raising only $17M, punching well above its weight class.

The Korean biopharma industry in 2025 was marked by some major deals involving smaller companies, while the improving investment climate could see further activity in selected areas in 2026.

Despite recent setbacks in the field, big pharma still appears to have faith in the tau approach to Alzheimer's, as evidenced by Sanofi's new $1bn-plus deal with Korean venture ADEL for an early stage candidate.

In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.

The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.

Private Company Edition: Braveheart Bio licensed its selective cardiac myosin inhibitor from Hengrui. Also, Arena BioWorks shuts down after raising $500m in 2024, GHO Capital closed a €2.5bn ($2.9bn) private equity fund and new cash brings Tubulis’s series C to €344m ($401m).

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.